Literature DB >> 31325604

Integrative Chinese herbal medicine therapy reduced the risk of type 2 diabetes mellitus in patients with polycystic ovary syndrome: A nationwide matched cohort study.

Wan-Ting Liao1, Cheng-Chiung Su2, Ming-Tsung Lee3, Chia-Jung Li4, Cheng-Li Lin5, Jen-Huai Chiang6, Hung-Rong Yen7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Polycystic ovary syndrome (PCOS) is a common condition that affects 5%-10% of women of reproductive age worldwide. Patients with PCOS have a high degree of insulin resistance and are at an increased risk of developing type 2 diabetes mellitus (T2DM). The currently available therapeutic approaches for PCOS mainly focus on symptomatic treatment. AIM OF THE STUDY: This study aimed to determine whether Chinese herbal medicine (CMH)-based interventions could reduce the risk of T2DM in PCOS patients.
MATERIALS AND METHODS: This retrospective study randomly selected 1 million enrollees from the National Health Insurance Database and identified 3797 patients who were newly diagnosed with PCOS in 1997-2010. After 1:1 frequency-matched by age, diagnosis of PCOS year and index days, we selected 342 eligible patients in each group.
RESULTS: The incidence of T2DM in the CHM group was significantly lower than that in the non-CHM group (hazard ratio = 0.31; 95% confidence interval, 0.15-0.64; p = 0.0014) after a mean follow-up period of 5.2 years (4.20 years for the comparison cohort). Five herbal formulas and two single herbs showed protective effects, and Paeonia lactiflora was a common ingredient in the five formulas.
CONCLUSIONS: Thus, CHM may help prevent T2DM-related complications in patients with PCOS. Further clinical and pharmacological analysis based on these findings is expected in the future.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  National health insurance research database; Polycystic ovary syndrome; Traditional Chinese medicine; Type 2 diabetes mellitus

Year:  2019        PMID: 31325604     DOI: 10.1016/j.jep.2019.112091

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: a retrospective cohort study.

Authors:  Xiaoming Pan; Yinger Gu; Xian Zhang; Biwei Shi; Long Cui; Fangfang Wang; Fan Qu
Journal:  Integr Med Res       Date:  2021-09-08

2.  Effects of Bu Shen Hua Zhuo formula on the LPS/TLR4 pathway and gut microbiota in rats with letrozole-induced polycystic ovary syndrome.

Authors:  Yang Wang; Hui Xiao; Yanxia Liu; Qing Tong; Yanyan Yu; Bing Qi; Xiaoling Bu; Tianyuan Pan; Yu Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

3.  An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies.

Authors:  Min-Han Chi; Jung Chao; Chien-Yu Ko; Shyh-Shyun Huang
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

4.  Chinese herbal medicine on treating obese women with polycystic ovary syndrome: A systematic review and meta-analysis protocol.

Authors:  Ning Ding; Rensong Yue; Lizhen Wang; Hongjing Yang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.